Predicting liver cancer return after surgery with a blood test
Part of Cancer clinical trials.
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have early-stage liver cancer (stage 0, A, or B) and are scheduled for surgery to remove it
- You are generally active and able to take care of yourself (ECOG score 0-1)
- Your liver function is good (Child-Pugh class A)
- You have not had any previous cancer treatment for this tumor
- Your blood test results are within normal range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a simple blood test (called ctDNA) can predict if liver cancer will come back after surgery. It compares the blood test to a standard lab result from the removed tumor, which may help doctors plan better follow-up care.
This trial uses a test on your tumor (an 'organoid') to pick which medicines might work best for you after surgery. The goal is to lower the chance of your liver cancer coming back.
This trial uses a simple blood test to check for signs of liver cancer coming back after surgery. It may help doctors catch a return earlier and guide further treatment.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Hear when a new Hepatocellular Carcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.